Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of WAL0921 in Patients With Glomerular Kidney Diseases and Proteinuria

NCT06466135 is registered in ClinicalTrials.gov with Walden Biosciences as lead sponsor.

NCT NCT06466135
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06466135 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of WAL0921 in Patients With Glomerular Kidney Diseases and Proteinuria
Lead sponsor
Walden Biosciences
Phase
Phase 2
Overall status
Recruiting
Start date
July 2, 2024
Completion date
June 30, 2027
Enrollment
96 (estimated)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic nephropathies, minimal change disease, primary focal segmental glomerulosclerosis, primary immunoglobulin a nephropathy, primary membranous nephropathy